|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OSBP |
Gene summary for OSBP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OSBP | Gene ID | 5007 |
| Gene name | oxysterol binding protein | |
| Gene Alias | OSBP1 | |
| Cytomap | 11q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | P22059 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5007 | OSBP | HTA11_347_2000001011 | Human | Colorectum | AD | 3.24e-07 | 3.84e-01 | -0.1954 |
| 5007 | OSBP | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.97e-02 | 3.87e-01 | 0.294 |
| 5007 | OSBP | HTA11_99999965104_69814 | Human | Colorectum | MSS | 6.45e-03 | 2.53e-01 | 0.281 |
| 5007 | OSBP | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.80e-02 | 4.11e-01 | 0.3859 |
| 5007 | OSBP | A015-C-203 | Human | Colorectum | FAP | 1.07e-08 | -1.67e-01 | -0.1294 |
| 5007 | OSBP | A001-C-108 | Human | Colorectum | FAP | 3.31e-04 | -2.78e-03 | -0.0272 |
| 5007 | OSBP | A002-C-205 | Human | Colorectum | FAP | 2.21e-04 | -1.52e-01 | -0.1236 |
| 5007 | OSBP | A015-C-006 | Human | Colorectum | FAP | 2.70e-02 | -9.12e-02 | -0.0994 |
| 5007 | OSBP | A002-C-114 | Human | Colorectum | FAP | 4.09e-03 | -9.21e-02 | -0.1561 |
| 5007 | OSBP | A015-C-104 | Human | Colorectum | FAP | 2.06e-08 | -5.46e-02 | -0.1899 |
| 5007 | OSBP | A001-C-014 | Human | Colorectum | FAP | 5.91e-06 | -1.63e-01 | 0.0135 |
| 5007 | OSBP | A002-C-016 | Human | Colorectum | FAP | 1.74e-05 | -1.51e-01 | 0.0521 |
| 5007 | OSBP | A002-C-116 | Human | Colorectum | FAP | 1.81e-08 | -9.00e-02 | -0.0452 |
| 5007 | OSBP | A018-E-020 | Human | Colorectum | FAP | 3.18e-04 | -1.63e-01 | -0.2034 |
| 5007 | OSBP | F034 | Human | Colorectum | FAP | 1.27e-04 | -1.35e-01 | -0.0665 |
| 5007 | OSBP | F072B | Human | Colorectum | FAP | 1.01e-02 | -1.24e-01 | 0.257 |
| 5007 | OSBP | LZE4T | Human | Esophagus | ESCC | 6.27e-04 | 9.86e-02 | 0.0811 |
| 5007 | OSBP | LZE7T | Human | Esophagus | ESCC | 3.98e-04 | 1.35e-01 | 0.0667 |
| 5007 | OSBP | LZE24T | Human | Esophagus | ESCC | 1.28e-13 | 2.83e-01 | 0.0596 |
| 5007 | OSBP | P2T-E | Human | Esophagus | ESCC | 1.91e-11 | 1.31e-01 | 0.1177 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
| GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
| GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
| GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
| GO:00454445 | Cervix | CC | fat cell differentiation | 53/2311 | 229/18723 | 3.72e-06 | 9.75e-05 | 53 |
| GO:19016538 | Cervix | CC | cellular response to peptide | 72/2311 | 359/18723 | 1.89e-05 | 3.48e-04 | 72 |
| GO:00512713 | Cervix | CC | negative regulation of cellular component movement | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
| GO:00400133 | Cervix | CC | negative regulation of locomotion | 76/2311 | 391/18723 | 3.47e-05 | 5.60e-04 | 76 |
| GO:20001463 | Cervix | CC | negative regulation of cell motility | 71/2311 | 359/18723 | 3.47e-05 | 5.60e-04 | 71 |
| GO:00303363 | Cervix | CC | negative regulation of cell migration | 68/2311 | 344/18723 | 5.11e-05 | 7.70e-04 | 68 |
| GO:00434349 | Cervix | CC | response to peptide hormone | 77/2311 | 414/18723 | 1.40e-04 | 1.70e-03 | 77 |
| GO:00713757 | Cervix | CC | cellular response to peptide hormone stimulus | 57/2311 | 290/18723 | 2.32e-04 | 2.59e-03 | 57 |
| GO:00328698 | Cervix | CC | cellular response to insulin stimulus | 42/2311 | 203/18723 | 4.95e-04 | 4.83e-03 | 42 |
| GO:00518964 | Cervix | CC | regulation of protein kinase B signaling | 39/2311 | 185/18723 | 5.25e-04 | 5.10e-03 | 39 |
| GO:00518973 | Cervix | CC | positive regulation of protein kinase B signaling | 28/2311 | 120/18723 | 5.90e-04 | 5.59e-03 | 28 |
| GO:00434913 | Cervix | CC | protein kinase B signaling | 43/2311 | 211/18723 | 5.95e-04 | 5.60e-03 | 43 |
| GO:00328688 | Cervix | CC | response to insulin | 50/2311 | 264/18723 | 1.28e-03 | 1.02e-02 | 50 |
| GO:00108834 | Cervix | CC | regulation of lipid storage | 15/2311 | 57/18723 | 3.13e-03 | 2.05e-02 | 15 |
| GO:00082865 | Cervix | CC | insulin receptor signaling pathway | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
| GO:00347645 | Cervix | CC | positive regulation of transmembrane transport | 40/2311 | 219/18723 | 6.97e-03 | 3.76e-02 | 40 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OSBP | SNV | Missense_Mutation | c.1295N>G | p.Ser432Cys | p.S432C | P22059 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| OSBP | SNV | Missense_Mutation | rs765405208 | c.2255N>T | p.Ala752Val | p.A752V | P22059 | protein_coding | tolerated(0.07) | possibly_damaging(0.523) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| OSBP | SNV | Missense_Mutation | novel | c.1429N>A | p.Ala477Thr | p.A477T | P22059 | protein_coding | deleterious(0.03) | probably_damaging(0.992) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| OSBP | SNV | Missense_Mutation | novel | c.866N>C | p.Lys289Thr | p.K289T | P22059 | protein_coding | deleterious(0) | possibly_damaging(0.864) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| OSBP | SNV | Missense_Mutation | c.2163N>T | p.Gln721His | p.Q721H | P22059 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| OSBP | SNV | Missense_Mutation | c.1618N>T | p.Arg540Cys | p.R540C | P22059 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OSBP | SNV | Missense_Mutation | c.2163N>C | p.Gln721His | p.Q721H | P22059 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| OSBP | SNV | Missense_Mutation | novel | c.209N>G | p.Pro70Arg | p.P70R | P22059 | protein_coding | tolerated_low_confidence(0.12) | benign(0.02) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| OSBP | SNV | Missense_Mutation | novel | c.208N>A | p.Pro70Thr | p.P70T | P22059 | protein_coding | tolerated_low_confidence(0.17) | benign(0.007) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| OSBP | SNV | Missense_Mutation | novel | c.1567N>T | p.His523Tyr | p.H523Y | P22059 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9UO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |